Takeda Pharmaceutical anunció el jueves 18 de octubre que la Comisión de Comercio Justo de Japón ha dado luz verde a su adquisición de Shire por US$62,000 millones de dólares, lo que acercó a la firma japonesa a cerrar un acuerdo que lo convertirá en uno de los 10 principales fabricantes de medicamentos del mundo. El acuerdo, que será la mayor compra en el extranjero por parte de una empresa japonesa, ya ha recibido la autorización incondicional de los reguladores en los Estados Unidos, Brasil y China.
Featured News
Musicians Union Takes Warner and Universal to Court Over AI Training Rights
Jun 9, 2026 by
CPI
Massachusetts Lawmakers Unanimously Pass Comprehensive Privacy Protections
Jun 9, 2026 by
CPI
Nuvei Nears $2.7 Billion Deal to Acquire Payoneer, Sources Say
Jun 9, 2026 by
CPI
EU Rejects Apple’s Claims Over Siri AI Delay in Europe
Jun 9, 2026 by
CPI
Pennsylvania Moves to Tame Data Center Boom With New Development Standards
Jun 9, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – (Geo)Political Antitrust
May 28, 2026 by
CPI
Competition Policy in Turbulent Geopolitical Times
May 28, 2026 by
Christophe Carugati & Annabelle Gawer
The New Political Determinants of U.S. Antitrust Policy
May 28, 2026 by
Aziz Z. Huq
The Geopolitical Rewiring of Antitrust
May 28, 2026 by
Hayane C. Dahmen
Three Strikes Against Political Antitrust
May 28, 2026 by
Nolan McCarty & Sepehr Shahshahani